Chief Healthcare Executive September 2, 2024
Health systems decried the pharma giant for moving away from discounts and asking providers to submit rebates for two popular drugs.
Hospitals are pushing back against Johnson & Johnson’s planned changes to price breaks through the federal 340B drug discount program.
Johnson & Johnson is planning to change its policy on two drugs: Xarelto, a blood thinner, and Stelara, a drug for Crohn’s disease and colitis. Instead of giving hospitals in the 340B program reduced prices at the time of purchase, Johnson & Johnson says hospitals will now need to submit applications for rebates and the company will reimburse them. The company is making the new policy effective Oct. 15.
Both Xarelto and Stelara are among the first group of...
Today's Sponsors
Today's Sponsor